CHAD Thompson grappled with a silent problem for 20 years – he couldn’t pee properly, and it was a constant source of anxiety ...

Padcev is approved for use in combination with the programmed death 1 inhibitor Keytruda (pembrolizumab) or Keytruda QLEX (pembrolizumab and berahyaluronidase alfa-pmph) as neoadjuvant treatment and ...

A research team at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) has developed a radiopharmaceutical molecule marker that ...

The combination of Keytruda and Padcev is taking another major step toward securing its position as a leading therapy in the treatment of bladder cancer. The PD-1/antibody-drug conjugate pairing ...

By default, metachronous bladder recurrences after UTUC surgery have been managed similarly to primary non-muscle invasive bladder cancer.

Study results are based on Surveillance, Epidemiology, and End Results-Medicare data for 166,581 patients receiving surgery or radiation for localized prostate cancer.

An update from the phase 2 LEGEND trial shows that the investigational nonviral gene therapy detalimogene voraplasmid has achieved a 62% complete response rate at six months in patients with high-risk ...

Theralase Technologies (USOTC:TLTFF) signed a clinical development agreement with Ferring Pharmaceuticals, a top name in ...

While the current approval focuses on the second-line setting, research is already moving into earlier stages of the disease.The ongoing SunRISe-3 trial (NCT05714202) is testing TAR-200 head-to-head ...

For individuals facing fear, uncertainty and repeated procedures associated with recurrent low-grade intermediate-risk bladder tumors, timely access to treatment can be critical. ZUSDURI, the first ...